SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Gary105 who wrote (139)1/14/1998 9:02:00 AM
From: yosi s  Respond to of 340
 
Teva been a roller coaster. They are mostly generic and getting more product and enlarging their market. But expectation where for revenues of copaxone,propretary drug, also awaiting Change in Israeli patent law,(tailored for teva). there are unkown with copaxone. If sale start to increase then yes teva will soar. I dont know if packaing and storage was hinderance (previously) to its use. or the Rx are not there. But once Teva moves it does so rapidly. Down side risk is minimal in the mid 40.



To: Gary105 who wrote (139)1/14/1998 10:43:00 AM
From: Dana Breite  Read Replies (1) | Respond to of 340
 
Hi, Gary - I believe the $3.28 estimate is for FY1997. The '98 eps estimate is $3.90. These estimates are more than likey including a contribution from Copaxone. If Teva meets these numbers, then it surely should exceed $70 with a growth rate in excess of 35%. Let's hope the analysts are on target. Good luck to all, Dana


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News